Daniel J Jackson, Leonard B Bacharier, Wanda Phipatanakul, Lawrence Sher, Christian Domingo, Nikolaos Papadopoulos, Brian Modena, Ning Li, Changming Xia, Mohamed A Kamal, Myles Dillon, Kelley Wolfe, Rebecca Gall, Nikhil Amin, Leda P Mannent, Elizabeth Laws, Paul J Rowe, Juby A Jacob-Nara, Yamo Deniz, David J Lederer, Megan Hardin, Christine Xu
BACKGROUND: Type 2 inflammation is common in children with asthma. Dupilumab, a human antibody, blocks signaling of interleukin-4/-13, key and central drivers of type 2 inflammation. In the VOYAGE (NCT02948959) study, dupilumab reduced severe asthma exacerbations and improved lung function in children aged 6-11 years with uncontrolled, moderate-to-severe asthma. OBJECTIVE: To assess pharmacokinetics of dupilumab and type 2 biomarker changes in children with type 2 asthma in VOYAGE...
March 21, 2023: Annals of Allergy, Asthma & Immunology